



Therapeutic antibodies against cancer:
tools and models to understand and improve their efficacy

GDR ACCITH Meeting Automnal

Montpellier 27 Novembre 2013

Salon du Belvédère

Le Corum - Esplanade Charles De Gaulle

The research network on Antibodies and Therapeutic Targeting (GDR 3260 « Anticorps et ciblage thérapeutique ») is pleased to announce its 2013 Forum which will be held in Montpellier on November 27th. Devoted to **therapeutic antibodies against cancer: tools and models to understand and improve their efficacy**, the meeting will gather international experts who will exchange their point-of-view on the state-of-the-art and perspectives of this therapeutic domain.

Inscription gratuite mais obligatoire
avant le 19 novembre

Document à retourner par mail ou par fax à Annie Gauvineau
secimmun@med.univ-tours.fr fax : 02 18 37 06 96

Nom / Prénom :

Nom du Laboratoire / de la société:

N° de téléphone professionnel :

Adresse e.mail :

Assistera aux sessions scientifiques :

OUI

NON

Rayer la mention inutile

Participera au déjeuner :

OUI

NON

Rayer la mention inutile

Scientific program

08:00 | 08:45 Welcome

08:45 | 09:00 Introduction

09:00 | 10:30 Session 1

Panorama on the therapeutic antibodies currently used in the clinic, the potentials, the challenges and the limitations

Véronique Blanc, Head of Biologics Discovery, Oncology Sanofi

Strategies for the isolation of innovative and original antibodies

James D Marks, School of Medicine, University of California, San Francisco, USA

10:30 | 11:00 Coffee break

11:00 | 12:30 Session 2

The power of humanized mice in translational research

Anja Kathrin Wege, Dpt. of Gynecology and Obstetrics, Caritas Hospital St. Josef, University of Regensburg, Germany

Personalized medicine for the next generation therapies: Challenges and new Strategies

Fabien Gaire, Global Head Pathology and Tissue Analysis, Roche Diagnostics, Germany

12:30 | 14:00 Lunch

14:00 | 15:00 Selected abstracts: 3 x 20 minutes

15:00 | 17:15 Session 3

ImmunoPET using pretargeted peptide labeled with ⁶⁸Ga in CEA positive tumors

Caroline Rousseau, Nuclear Medicine Department, Comprehensive Cancer Center ICO, Gauducheau, Saint Herblain, France

Exploiting innate immune populations to enhance the efficacy of therapeutic antibodies in cancer

Hans van der Vliet, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

ATL101 (Lutetium-177 huJ591 anti-PSMA mAb) clinical results in M+ castrate resistant prostate cancer patients

Jean-Marc Le Doussal, Atlab Pharma, Nantes, France

Scientific committee

Azria David

Cartron Guillaume

Cerutti Martine

Chardès Thierry

Larbouret Christel

Lefranc Marie-Paule

Martineau Pierre

Navarro-Teulon Isabelle

Pèleguin André

Peleguin Mireia

Poul Marie-Alix

Robert Bruno

Watier Hervé

Organization committee

Daguet Arnaud

Gauvineau Annie

Bonnemaison Marc